Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347056 | 0.98 | CYP1A2 (0.44) | CYP1A2NR4A1NR4A2NR4A3ALDH1A1 | |
| SCHEMBL30785066 | 0.98 | CYP1A2 (0.44) | CYP1A2NR4A1NR4A2NR4A3ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL21314237 | 0.96 | CYP1A2 (0.43) | CYP1A2NR4A1NR4A2NR4A3ALDH1A1 | |
| SCHEMBL28136648 | 0.96 | CYP1A2 (0.43) | CYP1A2NR4A1NR4A2NR4A3ALDH1A1 | |
| Formaldehyde SCHEMBL11755336 | 0.94 | CYP1A2 (0.41) | CYP1A2NR4A1NR4A2NR4A3ALDH1A1 | |
| SCHEMBL21314245 | 0.84 | CDYL (0.44) | CYP1A2ALDH1A1TDP1TSHRKDM4E | |
| SCHEMBL4649800 | 0.82 | ALDH1A1 (0.37) | CYP1A2NR4A1NR4A2NR4A3ALDH1A1 | |
| SCHEMBL21314240 | 0.79 | ALDH1A1 (0.42) | CYP1A2ALDH1A1CYP2A6TDP1KDM4E | |
| N-Benzylmethylamine SCHEMBL28137345 | 0.79 | KDM4E (0.49) | CYP1A2TSHRKDM4ECYP3A4ACP3 | |
| SCHEMBL11859134 | 0.78 | G6PD (0.48) | ALDH1A1TDP1TSHRHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022209944-A1 | DENTAL POLYMERIZATION KIT | サンメディカル株式会社 | 2022-10-06 | — | — | WO | disclosed |
| EP-3148371-B1 | REACTIVE MICRO APPLICATOR WITH METAL-CONTAINING ADDITIVES FOR USE IN DENTAL ADHESIVES | KULZER & CO GMBH (DE) | 2019-09-04 | — | — | EP | disclosed |
| CN-105906537-B | （Z）The One-step Synthesis method of formula sulfonyl enoic acid ester compounds | 湖南科技学院 | 2017-12-15 | — | — | CN | disclosed |
| CN-105906537-A | One-pot synthesis method of (Z)-type sulfonyl olefine acid ester compound | 湖南科技学院 | 2016-08-31 | — | — | CN | disclosed |
| US-9067949-B2 | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2668191-A2 | BENZOFURO[3,2-C]PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA | Albany Molecular Research, Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8575186-B2 | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| WO-2012099952-A2 | BENZOFURO[3,2-C] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184531-A1 | BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110112122-A1 | EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-5990105-A | POSSESS A SELECTIVE AFFINITY TO 5HT-6 RECEPTORS; TREATING OR PREVENTING PSYCHOSES, SCHIZOPHRENIA, MANIC DEPRESSIONS, DEPRESSIONS, NEUROLOGICAL DISORDERS, PARKINSON'S, AMYOTROPHIC LATERAL SCLEROSIS, ALZHEIMER'S AND HUNTINGTON'S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1999-11-23 | — | — | US | disclosed |
| CN-1231287-A | Benzosulfone derivatives | HOFFMANN LA ROCHE (CH) | 1999-10-13 | — | — | CN | disclosed |
| EP-0930302-A2 | Benzosulfone derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 1999-07-21 | — | — | EP | disclosed |
| EP-0405389-B1 | Process for producing an aromatic compound | MITSUBISHI CHEM IND (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5159082-A | Catalytic coupling of an aromatic sulfinic acid with an aromatic halogen compound | MITSUBISHI KASEI CORPORATION (JP) | 1992-10-27 | — | — | US | disclosed |
| EP-0304190-B1 | (ARYLSULPHONYL)NITROMETHANES, PROCESS FOR THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-08 | — | — | EP | disclosed |
| EP-0405389-A1 | Process for producing an aromatic compound | Mitsubishi Chemical Corporation (JP) | 1991-01-02 | — | — | EP | disclosed |
| EP-0342939-A1 | Silver halide photographic light sensitive material | KONICA CORPORATION (JP) | 1989-11-23 | — | — | EP | disclosed |
| CN-1031529-A | Pharmaceutical composition | ICI PLC (GB) | 1989-03-08 | — | — | CN | disclosed |
| EP-0304190-A1 | (Arylsulphonyl)nitromethanes, process for their preparation and use in pharmaceutical compositions | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112122-A1 | EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF | HTR6, HTR3B, HTR1B | CYP1A2 149/4885NR4A1 1008/4885NR4A2 1174/4885 |
| US-20120184531-A1 | BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA | HTR6, HTR5A, HTR2C | CYP1A2 131/4885NR4A1 396/4885NR4A2 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.